Modulation of the defective natural killer activity seen in thalassaemia major with desferrioxamine and alpha-interferon. 1987

A N Akbar, and P A Fitzgerald-Bocarsly, and P J Giardina, and M W Hilgartner, and R W Grady
Department of Pediatrics, Cornell University Medical Center, New York, NY 10021.

We previously observed that natural killer (NK) activity toward K562 cells is markedly depressed in patients with beta-thalassaemia major. Here we report that these patients also exhibit significantly decreased (P less than 0.005) NK cytotoxicity against human fibroblasts infected with herpes simplex virus-type 1 (HSV-1) and that the amount of alpha-interferon (alpha-IFN) generated during the latter assays is significantly less than normal (P less than 0.005). This decreased production of alpha-IFN may account in part for the decreased NK activity seen in the thalassaemia patients. On the other hand, the cytotoxicity of their mononuclear cells (MNC) toward both K562 cells and HSV-1-infected fibroblasts could be augmented to the same extent as that of normal MNC by preincubation with alpha-IFN suggesting that thalassaemia MNC are capable of responding to this lymphokine despite their reduced ability to produce it. Moreover, preincubation of thalassaemia MNC with desferrioxamine (DFO), an iron-chelating agent, consistently increased the lysis of K562 cells indicating that the transfusion-induced iron overload which these patients experience may also contribute to the defective NK function seen in this disease. We have now found that preincubation of such MNC with DFO has no effect upon production of alpha-IFN when the MNC are cocultured with either HSV-1-infected fibroblasts or K562 cells. Combining DFO and alpha-IFN resulted in an increase in the NK activity of both normal and thalassaemia MNC against the two targets which was greater than that with alpha-IFN alone. In fact, preincubation of thalassaemia cells with this combination increased their NK activity toward K562 targets to that of untreated normal cells. This was true when either unfractionated MNC or NK-enriched fractions were used as effector cells. These results suggest that DFO and alpha-IFN enhance NK activity by different mechanisms, both of which appear to be reversibly impaired in thalassaemia patients.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006561 Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.) Herpes Simplex Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013789 Thalassemia A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. Thalassemias

Related Publications

A N Akbar, and P A Fitzgerald-Bocarsly, and P J Giardina, and M W Hilgartner, and R W Grady
January 1985, Cancer immunology, immunotherapy : CII,
A N Akbar, and P A Fitzgerald-Bocarsly, and P J Giardina, and M W Hilgartner, and R W Grady
January 1991, Acta neurochirurgica,
A N Akbar, and P A Fitzgerald-Bocarsly, and P J Giardina, and M W Hilgartner, and R W Grady
January 1980, Annals of the New York Academy of Sciences,
A N Akbar, and P A Fitzgerald-Bocarsly, and P J Giardina, and M W Hilgartner, and R W Grady
April 1985, Neurology,
A N Akbar, and P A Fitzgerald-Bocarsly, and P J Giardina, and M W Hilgartner, and R W Grady
May 1982, British medical journal (Clinical research ed.),
A N Akbar, and P A Fitzgerald-Bocarsly, and P J Giardina, and M W Hilgartner, and R W Grady
April 1982, British medical journal (Clinical research ed.),
A N Akbar, and P A Fitzgerald-Bocarsly, and P J Giardina, and M W Hilgartner, and R W Grady
January 1989, Journal of cancer research and clinical oncology,
A N Akbar, and P A Fitzgerald-Bocarsly, and P J Giardina, and M W Hilgartner, and R W Grady
September 1990, Cancer research,
A N Akbar, and P A Fitzgerald-Bocarsly, and P J Giardina, and M W Hilgartner, and R W Grady
September 1966, Helvetica paediatrica acta,
A N Akbar, and P A Fitzgerald-Bocarsly, and P J Giardina, and M W Hilgartner, and R W Grady
September 1983, Annals of neurology,
Copied contents to your clipboard!